Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

3 of 3 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 1
2(66.7%)
Phase 2
1(33.3%)
3Total
Phase 1(2)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT01856868Phase 1Completed

Use of (-)-Epicatechin in the Treatment of Becker Muscular Dystrophy (Pilot Study)

Role: lead

NCT02964377Phase 1Completed

Plus Epicatechin Duchenne Muscular Dystrophy in Non-ambulatory Adolescents

Role: lead

NCT03236662Phase 2Completed

(-)- Epicatechin Becker Muscular Dystrophy

Role: lead

All 3 trials loaded